Stockreport

Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency

Kamada Ltd. - Ordinary Shares  (KMDA) 
Last kamada ltd. - ordinary shares earnings: 2/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: kamada.com/investors.php
PDF REHOVOT, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first pat [Read more]